-23.1% · 90d
$54.02
+0.82 (+1.54%)
After-Hours $54.02(+0.00)
News
(1)April 2026
MNPR presents superior Phase 3 data for ALXN1840 in Wilson disease
MNPRMonopar Therapeutics
# 📝 What This Document Is 📰 This filing is an 8-K, which is a mandatory SEC filing used to quickly announce important, material events about a company. In this case, Monopar Therapeutics (MNPR) is using it to announce that they are presenting critical Phase 3 clinical trial data for their drug, A
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%